Christopher Raymond analyst PIPER SANDLER

Currently out of the existing stock ratings of Christopher Raymond, 369 are a BUY (80.57%), 83 are a HOLD (18.12%), 6 are a SELL (1.31%).

Christopher Raymond

Work Performance Price Targets & Ratings Chart

Analyst Christopher Raymond works at PIPER SANDLER with a stock forecast success ratio of 46.41% fulfilled within 161.31 days on average.

Christopher Raymond’s has documented 916 price targets and ratings displayed on 39 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BIIB, Biogen at 14-Feb-2024.

Wall Street Analyst Christopher Raymond

Analyst best performing recommendations are on ALXO (ALX ONCOLOGY HOLDINGS ).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 5/31/2018. The price target of $35 was fulfilled within 4 days with a profit of $9.28 (36.08%) receiving and performance score of 90.2.

Average potential price target upside

ABBV AbbVie ACRS Aclaris Therapeutics AIMT Aimmune Therapeutics AKBA Akebia Ther ALVR Allovir  ALXN Alexion Pharmaceuticals AMAG AMAG Pharmaceuticals AMGN Amgen ARDX Ardelyx BIIB Biogen BMRN Biomarin Pharmaceutical COGT Cogent Biosciences DCPH Deciphera Pharmaceuticals LLC GRAY Graybug Vision INO Inovio Pharmaceuticals ONCR Oncorus  RARE Ultragenyx REGN Regeneron Pharmaceuticals APTX Aptinyx BPMC Blueprint Medicines Corp CELG Celgene INZY Inozyme Pharma  MGTX MeiraGTx Holdings PLC OTIC Otonomy RIGL Rigel Pharmaceuticals BOLD Audentes Therapeutics CBIO Catalyst Biosciences KNTE Kinnate Biopharma  PRVL Prevail Therapeutics SLDB Solid Biosciences LLC XLRN Acceleron Pharma BCRX BioCryst Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd NUVL Nuvalent ALXO Alx Oncology Holdings  KPTI Karyopharm Therapeutics RMTI Rockwell Medical SPHS Sophiris Bio VECT VectivBio Holding AG

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

189

$13.86 (7.91%)

181

17 days ago

9/13 (69.23%)

$20.33 (12.05%)

256

Buy

185

$9.86 (5.63%)

175

17 days ago

11/12 (91.67%)

$16.33 (9.68%)

140

Buy

195

$19.86 (11.34%)

180

17 days ago

7/10 (70%)

$26.33 (15.61%)

402

Hold

156

$-19.14 (-10.93%)

167

2 months 5 days ago

2/2 (100%)

$2.58 (1.68%)

109

Buy

173

$-2.14 (-1.22%)

122

2 months 12 days ago

1/3 (33.33%)

$21.76 (14.39%)

58

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Christopher Raymond is most bullish on?

Potential upside of $102.52 has been obtained for BIIB (BIOGEN)

Which stock is Christopher Raymond is most reserved on?

Potential downside of -$69.89 has been obtained for REGN (REGENERON PHARMACEUTICALS)

What Year was the first public recommendation made by Christopher Raymond?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?